Jefferies Says No Changes to Ests on Amgen (AMGN) Amid Parsabiv CRL; Affirms at 'Buy'

August 25, 2016 7:43 AM EDT
Get Alerts AMGN Hot Sheet
Price: $153.80 --0%

Rating Summary:
    18 Buy, 14 Hold, 2 Sell

Rating Trend: = Flat

Today's Overall Ratings:
    Up: 14 | Down: 24 | New: 13
Trade AMGN Now!
Join SI Premium – FREE

Get daily under-the-radar research with's Stealth Growth Insider Get your 2-Wk Free Trial here.

Jefferies affirms Amgen (Nasdaq: AMGN) with a Buy rating and $198 price target following receipt of FDA CRL on Parsabiv.

The firm commented, On positive Ph3 data, FDA approval of Parsabiv for treatment of secondary hyperparathyroidism was largely expected. Details of the CRL is undisclosed. While we can't accurately forecast timing of potential approval, as we've assumed a launch in 2017 (~$500M in 2022 sales vs. cons. $575M), at present we're not changing our estimates. Parsabiv represents a small part of our current valuation for Amgen (NPV of ~$2/sh on 50% probability-adjusted, ~1% of our PT of $198).

For an analyst ratings summary and ratings history on Amgen click here. For more ratings news on Amgen click here.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments, FDA

Related Entities

Jefferies & Co

Add Your Comment